<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03349931</url>
  </required_header>
  <id_info>
    <org_study_id>K-170102</org_study_id>
    <secondary_id>2017-A01518-45</secondary_id>
    <nct_id>NCT03349931</nct_id>
  </id_info>
  <brief_title>Prospective Multicenter Evaluation of the MycoGenie Kit for the Diagnosis of Invasive Aspergillosis</brief_title>
  <acronym>MYCOGENIE</acronym>
  <official_title>Prospective Multicenter Evaluation of the MycoGenie Kit for the Diagnosis of Invasive Aspergillosis in Hematological Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Société ADEMTECH SA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the performances of the real-time PCR ADEMTECH kit&#xD;
      of DNA extraction and detection of Aspergillus fumigatus in serum samples in patients at&#xD;
      high-risk for invasive aspergillosis (IA). DNA detection will be associated with detection of&#xD;
      TR34/L98H mutations in cyp51A gene, which confer azole resistance.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Accurate diagnosis of invasive pulmonary aspergillosis (IPA) in patients at high risk of&#xD;
      invasive fungal infection remains challenging due to difficulties in differentiating IPA from&#xD;
      pulmonary infections caused by other molds or bacteria on clinical and radiological grounds.&#xD;
      Therefore, culture-based microbiological diagnosis is of primary importance but requires&#xD;
      semi-invasive or invasive procedures, such as bronchoalveolar Lavage (BAL) or&#xD;
      computed-tomography (CT)-guided needle biopsy.&#xD;
&#xD;
      Alternate diagnostic methods include the detection of biomarkers, such as fungal antigens&#xD;
      (Aspergillus galactomannan [GM]) or DNA released by Aspergillus hyphae in host tissues. These&#xD;
      biomarkers are well recognized as early IPA predictors Recently, several clinical evaluations&#xD;
      to detect Aspergillus DNA, either in respiratory or in blood-based samples, have clearly&#xD;
      shown the diagnostic value of this biomarker. In addition, methodological recommendations&#xD;
      have been established for PCR protocols, and different standardized Aspergillus quantitative&#xD;
      PCR (qPCR) kits have been commercialized. These recent advances show that PCR is now mature&#xD;
      for routine use in clinical settings.&#xD;
&#xD;
      Another issue is the emergence of aspergillosis due to azole-resistant isolates. Acquired&#xD;
      azole resistance in A. fumigatus has been reported since 1997 and has emerged in many&#xD;
      countries, particularly in Europe, as well as on other continents. In some instances,&#xD;
      acquired resistance may be driven by antifungal selection in patients receiving long-term&#xD;
      therapy. Nevertheless, it seems that many azole-resistant strains originated in the&#xD;
      environment due to selection by azole fungicides used in agriculture. Azole resistance in A.&#xD;
      fumigatus is associated mainly with mutations in the cyp51A gene, and among several mutations&#xD;
      described, the most frequent is the mutation comprising a 34-bp tandem repeat (TR34) and the&#xD;
      L98H alteration. Since azoles are the recommended first-line treatment for IPA, the emergence&#xD;
      of azole resistance is worrisome and has been shown to be associated with an increased rate&#xD;
      of clinical failure. For these reasons, routine antifungal susceptibility testing of clinical&#xD;
      isolates has been recommended recently. Nevertheless, isolates are not always retrieved in&#xD;
      culture, particularly for patients with hematological malignancies. Therefore, molecular&#xD;
      detection of resistance may be a major advance for the management of patients with invasive&#xD;
      aspergillosis.&#xD;
&#xD;
      The aim of this study will be to validate the new MycoGENIE A. fumigatus real-time PCR kit&#xD;
      and to evaluate its performance on clinical samples for the detection of A. fumigatus and its&#xD;
      azole resistance. This multiplex assay detects DNA from the A. fumigatus species complex by&#xD;
      targeting the multicopy 28S rRNA gene and specific TR34 and L98H mutations in the single-copy&#xD;
      number cyp51A gene of A. fumigatus.&#xD;
&#xD;
      The study will be performed in hematological patients with high-risk of developping IA during&#xD;
      the course of chemotherapy. In these patients, bi-weekly detection of GM is routinely&#xD;
      performed in all centers in France. The PCR will be performed on the samples used for GM&#xD;
      detection. DNA will be extracted according to the manufacturer's protocol, using the&#xD;
      MycoGENIE kit for AutoMag solution. Real-time PCR for the detection of A. fumigatus DNA will&#xD;
      be performed using the MycoGENIE A. fumigatus real-time PCR kit (Ademtech, Pessac, France).&#xD;
&#xD;
      AI will be defined as proven or probable aspergillosis, according to EORTC criteria.&#xD;
&#xD;
      For each patient, clinical data will be collected in each center. These data include: EORTC&#xD;
      classification, type and duration of antifungal treatments, results of GM tests, results of&#xD;
      mycological cultures, and results of PCR tests (positivity and Ct values). For each patient a&#xD;
      case report form (CRF) will be filled and transfered to the investigating center for&#xD;
      analysis. Sensitivity, specificity, PPV and NPV of the PCR test will be calculated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 5, 2018</start_date>
  <completion_date type="Actual">January 20, 2020</completion_date>
  <primary_completion_date type="Actual">January 20, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Performance of PCR for Aspergillosis diagnosis</measure>
    <time_frame>6 months</time_frame>
    <description>Determination of the performances (Sensitivity, specificity, PPV and NPV) of the kit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection of azole resistance</measure>
    <time_frame>6 months</time_frame>
    <description>Detection of TR34 and L98H mutations in the A. fumigatus single-copy number gene cyp51A.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">350</enrollment>
  <condition>Invasive Aspergillosis in Patients With Onco-haematological Diseases</condition>
  <arm_group>
    <arm_group_label>Hematological patients</arm_group_label>
    <description>Hematological patients at high risk for invasive aspergillosis</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>DNA extraction and detection of Aspergillus fumigatus in serum samples</intervention_name>
    <description>Performances diagnostic test of the real-time PCR ADEMTECH kit of DNA extraction and detection of Aspergillus fumigatus in serum samples in patients at high-risk for invasive aspergillosis (IA).</description>
    <arm_group_label>Hematological patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Human sera (serum)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hematological patients at high risk for invasive aspergillosis, who can be classified&#xD;
        according to EORTC criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adult Patients (≥ 18 years) hospitalized in onco hematologic unit or in hematopoietic&#xD;
             stem cell transplantation (HSCT) unit&#xD;
&#xD;
          2. Patients with acute leukemia undergoing induction for AML, ALL, chimotherapy with&#xD;
             neutopenia &gt;10 days or Patients undergoing allogeneic stem cell chemotherapy&#xD;
             transplantation&#xD;
&#xD;
          3. Patients with biweekly screening for GM detection in serum&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient &lt; 18 years-old (minor)&#xD;
&#xD;
          2. Informed consent not available&#xD;
&#xD;
          3. Patient without affiliation to French social insurance&#xD;
&#xD;
          4. Patient without biweekly screening for GM detection in serum&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric DANNAOUI, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-Elisabeth BOUGNOUX, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Bordeaux, Groupe hospitalier</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de DIJON, Hôpital du bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille, Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes, Hôpital de Moncousu</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Necker - Enfants maladies (AP-HP)</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de RENNES, hôpital de Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Suarez F, Lortholary O, Buland S, Rubio MT, Ghez D, Mahé V, Quesne G, Poirée S, Buzyn A, Varet B, Berche P, Bougnoux ME. Detection of circulating Aspergillus fumigatus DNA by real-time PCR assay of large serum volumes improves early diagnosis of invasive aspergillosis in high-risk adult patients under hematologic surveillance. J Clin Microbiol. 2008 Nov;46(11):3772-7. doi: 10.1128/JCM.01086-08. Epub 2008 Sep 24.</citation>
    <PMID>18845828</PMID>
  </reference>
  <reference>
    <citation>Dannaoui E, Gabriel F, Gaboyard M, Lagardere G, Audebert L, Quesne G, Godichaud S, Verweij PE, Accoceberry I, Bougnoux ME. Molecular Diagnosis of Invasive Aspergillosis and Detection of Azole Resistance by a Newly Commercialized PCR Kit. J Clin Microbiol. 2017 Nov;55(11):3210-3218. doi: 10.1128/JCM.01032-17. Epub 2017 Aug 16.</citation>
    <PMID>28814586</PMID>
  </reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 17, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2017</study_first_posted>
  <last_update_submitted>December 3, 2020</last_update_submitted>
  <last_update_submitted_qc>December 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aspergillosis,</keyword>
  <keyword>qPCR</keyword>
  <keyword>allogenic haemopoietic stem-cell transplantation</keyword>
  <keyword>leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

